ArticleMolecular medicine reports2018
Overexpression of miR‑146a blocks the effect of LPS on RANKL‑induced osteoclast differentiation.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- A Nanomedicine Strategy: Spatiotemporally Programmed Delivery of Engineered Exosomes via Smart Scaffolds for Craniofacial Bone Regeneration.International journal of nanomedicine · 2026Review
- Exploring the regulatory roles of MicroRNAs on NF- ΚB target genes in individuals with apical periodontitis.Clinical oral investigations · 2025Article
- Emerging therapeutic strategies targeting bone signaling pathways in periodontitis.Journal of periodontal research · 2025Review
- Serum miR-146a as a diagnostic and predictive biomarker for osteoporosis and bisphosphonate treatment efficacy.American journal of translational research · 2025Article
- HSP90 Exacerbates Bone Destruction in Rheumatoid Arthritis by Activating TRAF6/NFATc1 Signaling.Inflammation · 2024Article
- MicroRNA-146a-loaded magnesium silicate nanospheres promote bone regeneration in an inflammatory microenvironment.Bone research · 2024Article
- Emerging role of mesenchymal stem/stromal cells (MSCs) and MSCs-derived exosomes in bone- and joint-associated musculoskeletal disorders: a new frontier.European journal of medical research · 2023Review
- Regulation of osteoclast-mediated bone resorption by microRNA.Cellular and molecular life sciences : CMLS · 2022Review
- Osteoclastogenesis in periodontal diseases: Possible mediators and mechanisms.Journal of oral biosciences · 2020Review
- Effects and Mechanism of lncRNA CRNDE on Sepsis-Induced Acute Kidney Injury.Analytical cellular pathology (Amsterdam) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept that inflammation serves a leading role in osteoclast‑induced bone loss under pathological circumstances is now widely accepted. In the present study, it was observed that lipopolysaccharides (LPSs) demonstrated a synergic effect on receptor activator of nuclear factor κ‑B ligand (RANKL)‑induced osteoclast differentiation in Raw264.7 cells, with increasing levels of multiple pro‑inflammatory cytokines including interleukin (IL)‑6, tumor necrosis factor‑α and IL‑1β. Furthermore, microRNA (miR)‑146a was highly induced by LPS and RANKL co‑stimulation during the process of osteoclast differentiation. Overexpression of miR‑146a inhibited osteoclast transformation by targeting the key regulators of nuclear factor (NF)‑κβ signaling, TNF receptor‑associated factor 6 and interleukin‑1 receptor‑associated kinase 1. The downstream activation of NF‑κβ signaling was also inhibited by transfection with a miR‑146a mimic. Altogether, the results of the present study demonstrated that miR‑146a prevents osteoclast differentiation induced by LPS and RANKL co‑stimulation, suggesting that miR‑146a may be a promising therapeutic target for treatment of inflammation mediated bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.